All Pharma News
Prilenia: Huntington`s, ALS Pridopidine Data At AAN 2024

Prilenia: Huntington`s, ALS Pridopidine Data At AAN 2024
BUSINESSWIRE
12 Apr 2024
Share Share
Prilenia Plans to Submit MAA in the EU for Pridopidine in Huntington’s Disease

Prilenia Plans to Submit MAA in the EU for Pridopidine in Huntington’s Disease
BUSINESSWIRE
12 Mar 2024
Share Share
Prilenia Announces Data in Support of Plans to Initiate Phase 3 Study in ALS

Prilenia Announces Data in Support of Plans to Initiate Phase 3 Study in ALS
BUSINESSWIRE
19 Jan 2024
Share Share
Prilenia Achieves Last Patient Last Visit in Phase 3 PROOF-HD Clinical Study

Prilenia Achieves Last Patient Last Visit in Phase 3 PROOF-HD Clinical Study
BUSINESSWIRE
28 Mar 2023
Share Share
Prilenia Announces Topline Results for Pridopidine in Phase 2 ALS Study

Prilenia Announces Topline Results for Pridopidine in Phase 2 ALS Study
BUSINESSWIRE
23 Feb 2023
Share Share
Prilenia searches for positive signs in phase 2 ALS fail

Prilenia searches for positive signs in phase 2 ALS fail
Annalee Armstrong FIERCE BIOTECH
23 Feb 2023
Share Share
Prilenia Expands Leadership Team, Appoints Anne Sullivan as CBO

Prilenia Expands Leadership Team, Appoints Anne Sullivan as CBO
BUSINESSWIRE
29 Sep 2022
Share Share
Prilenia Completes Enrollment Ahead of Schedule in HEALEY ALS Platform Trial

Prilenia Completes Enrollment Ahead of Schedule in HEALEY ALS Platform Trial
BUSINESSWIRE
05 Jan 2022
Share Share
Prilenia Receives FTD for Pridopidine for Huntington’s Disease

Prilenia Receives FTD for Pridopidine for Huntington’s Disease
BUSINESSWIRE
17 Nov 2021
Share Share
Going after Huntington`s disease again, ex-Teva R&D chief gets cash for Prilenia

Going after Huntington`s disease again, ex-Teva R&D chief gets cash for Prilenia
Max Gelman ENDPTS
04 Nov 2021
Share Share